Research Triangle park.

PositionTriangle

RESEARCH TRIANGLE PARK--Drug developer Liquidia Technologies signed a licensing deal with British pharmaceutical giant Glaxo-SmithKline, which will use Liquidia's nanotechnology with its products to create vaccines and other drugs for respiratory illnesses. The companies did not disclose an exact figure, but payments could total "several hundred million...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT